Feedback Share Discussion Threads

[lr2] 03/7/2023 11:43

One smart cookie IMHO.

[ducatiman] 30/6/2023 20:40

Another week of diminishing returns for shareholders.
I wonder if the executives salaries have diminished?
What will TO get a bonus for this year?



Walter Mitty!?

[lr2] 26/6/2023 21:21

Hey Duc, Antoine Saillant is the brains behind Bleepa / CareLocker as far as I can tell. He's probably well worth the salary he gets compared to others employed at Feedback plc.

He worked for Siemens Healthineers for almost 5 years before joining Feedback plc. Pretty sure he is one smart cookie.

[ducatiman] 26/6/2023 18:46

LR2, another nice title “head of product”! 4 years salary =£?
FybberF, I cling to the hope that Prof Shaw’s substantial on market buying was done with some idea that the potential will be delivered at some stage. However as a businessman I am appalled at the waste here.

[lr2] 26/6/2023 17:53

We sat down with our Head of Product Antoine Saillant to discuss the evolution of Bleepa and developing of a complex, regulated digital product that meets real-world medical needs. Read the full article here 👉

[ydderf] 26/6/2023 17:41

ducatiman - serious question, why don't you sell? The psychological cost must be great cumulatively over the years? Take a load off?

[digger2779] 26/6/2023 17:03

Just had a look at our financials on ADVFN and they haven't caught up with our 200 for 1 consolidation as we are showing a market cap of 2.87 billion!! If only, or maybe wonderboy isn't telling us something.

[ducatiman] 20/6/2023 17:33

So my uptake of the trading update was summised above. More bullsh1t.
Maybe it’s just me but this is how it was translated by another party, lol.

Feedback expects annual revenue boost; "exciting" opportunities ahead

[ducatiman] 20/6/2023 17:28

Have to hold fybberF to account here. He obviously didn’t read the update and obviously hasn’t followed Bleepa’s progress over the last three years.from the update:-

Bleepa v1.5 incorporates a number of advanced features that further strengthen the proposition including:

-- the ability to share the patient record to a clinician outside of the current hospital deployment, opening the potential for truly regional or national care delivery;

-- enhanced features for document capture such as document preview and categorisation enabling users to contribute to the patient record with virtually any medical information (referral letter, ECG trace, blood report, etc); and

-- improved messaging functionalities such as tagging teams and individuals and making structured notes to enable users to communicate even more intuitively, quickly and safely.

[ydderf] 19/6/2023 21:04

Ockham's Razor surely, the most likely explanation for no commercial interest is nobody's interested? TO has had years to prove otherwise. Another problem never discussed here is that much has changed in the last three or four years including advances in AI but as far as I can ascertain Bleepa is the same as three years ago...

[ducatiman] 19/6/2023 19:37

He could be correct but is anyone listening?
His last shot?

[lr2] 19/6/2023 15:00

Dr Thomas Oakley’s Post

I am pleased to share the news that I will be speaking at the All Party Parliamentary Group (APPG) for Diagnostics on Wednesday alongside Sir Mike Richards, Rhydian Phillips, Alexandra Pinches, Dr Katharine Halliday and Professor Michael Osborn. We will be addressing the challenges facing the CDC rollout and I will be advocating for the role of digital tools as the third pillar of core infrastructure, alongside investments in bricks & mortar and staffing. The NHS has made significant investment in the latter two but there is now a gaping hole in the digital elements of the CDC programme.

In 2021 I advocated that CDCs represented a once in a generation opportunity to fix our digital infrastructure - without the right digital foundations we will not unlock the full potential of the CDC programme to impact wait times.

We have now shown the impact of Bleepa on the CDC programme, having demonstrated a 70% reduction in patient wait times, without the need for additional clinical staff, all whilst generating a huge cash saving for the system.

I will be putting the case for national focus on digital commissioning to MPs during the APPG and will be pleased to represent wider industry suppliers, especially SMEs. If there is something that you would like me to take to the discussion then please DM me.

With winter pressures bearing down upon us the reality is that most physical builds will not deliver in time and staffing solutions are even further out. Only digital tools, adopted at pace across the system, can impact waiting lists and diagnostic workflows in time.

These solutions are here, but we need honest and robust conversations about commissioning them centrally and the decisions need to be made now on behalf of the system, regional commissioning is too slow to meet the needs of patients, both now and ahead of winter.

[ydderf] 19/6/2023 13:02

yump do you think that if they had an order they would not find 3 different ways to tell us and of course it would be included in a trading update, the term is not defined in the way you suggest. They have no need to sell stuff when they can raise a few more million every year or two. Shareholders get the management the deserve (think about it) most original shareholders have dumped and run over past years - why is that?

[digger2779] 19/6/2023 09:39

Have the vets and their horses kicked us into touch? Getting through cash at a rate of knots too!!

[yump] 19/6/2023 07:59

Trading updates don’t contain orders you tiresome little midge.

[ydderf] 19/6/2023 07:50

No orders then.....

[ducatiman] 19/6/2023 07:19

More blah, blah, blah.

[ducatiman] 13/6/2023 07:29

Oakley’s dreams V reality!

[lr2] 12/6/2023 17:38

Bringing the Hewitt review’s ideals to life.

Dr Tom Oakley, Feedback Medical’s CEO, looks at the next steps following the Hewitt review ahead of this week’s NHS ConfedExpo conference.

[ydderf] 11/6/2023 10:41

"IB Nimble, the handheld app which connects medical specialists in a secure environment and allows them to establish optimal treatment plans for their patients without having to physically meet, enabling for example a virtual 'tumour board'. IB Nimble is adaptable to any disease group. The Company has now secured its first commercial contract to install an operating network for clinical use of the app in a new disease area. Interest from other potential users is being stimulated by this initial installation and we are hopeful that further contracts will ensue in due course" From the IQAI annual report a few weeks ago.

"IB Nimble" (Imaging Biometrics) is owned by IQAI, which has a Standard listing, market.The main activity of IQAI is AI applied to medical diagnostics and other projects - dyor, however if comparing the market cap of IQAI with Feedback, the man on the Clapham Omnibus might might struggle to explain the apparent anomaly...

[lr2] 08/6/2023 15:57

Some reading to combat the loneliness.

Estimated Value £975,800,000 Excluding VAT.